Medicinal Plants | ~4 min read The market is splitting in two and pharma-grade botanical nutraceutical is one of them For years, the nutraceutical industry sourced botanical ingredients the same way the food industry sourced spices: in bulk, from commodity suppliers, with minimal documentation beyond a basic certificate of analysis. The primary selection criteria were price per kilogram and availability. For many products, this was adequate. A dried leaf blend destined for

BotaniX expertise | ~4 min read Dried plant material was the default, but that is changing. For most of the history of botanical ingredient supply, the standard format was simple: dried plant material, ground to a coarse or medium powder, shipped in bulk. Formulators received it, tested it, and worked with whatever particle size distribution the supplier delivered. The result was adequate for many applications, but it introduced variability at the formulation stage that man

Medicinal Plants | ~4 min read In and out products to enhance skin beauty and longevity The wall between cosmetics and nutrition is dissolving For decades, the skincare industry and the supplement industry operated as separate worlds. They served the same consumer, often with the same botanical species, but through entirely different supply chains, regulatory frameworks, and product development cultures. A cosmetics formulator sourcing Centella asiatica extract for a serum

The supply chain that nobody questioned For decades, the global botanical ingredients industry operated on a straightforward model: source raw plant material from tropical and subtropical regions where labour is inexpensive and biodiversity is abundant, process it through a chain of intermediaries, and deliver it to European manufacturers for formulation. The primary selection criteria were price and availability. The system worked well enough when nobody looked too closely a

B Corp is everywhere. But what does it mean for a biotech company producing high-tech botanicals?

The Forgotten Half of the Plant When we think of medicinal plants, we usually picture leaves, flowers, and stems. These aerial parts are the most accessible, the most studied, and the easiest to harvest at scale. But for many therapeutically important species, the root system contains a distinct and often more concentrated set of bioactive compounds that have been largely overlooked by the modern ingredients industry.

The Hidden Problem with Field-Grown Botanicals For centuries, medicinal plants have been cultivated in open fields or collected from the wild. This approach served traditional medicine well, but it falls short of the standards demanded by today’s pharmaceutical, cosmetic, and nutraceutical industries. Field-grown botanical ingredients carry inherent risks: soil-borne contaminants, pesticide residues, heavy metal accumulation, and batch-to-batch variation in active compound c

What Is the Nagoya Protocol and Why Should You Care? The Nagoya Protocol is an international agreement under the Convention on Biological Diversity that governs access to genetic resources and the fair sharing of benefits arising from their use. Adopted in 2010 and entering into force in 2014, it establishes a legal framework requiring that biological materials sourced from signatory countries are obtained with prior informed consent and that benefits from their commercial u

Traceability Is No Longer Optional The days when "natural origin" was a sufficient quality claim for botanical ingredients are over. Today’s regulatory environment, from EU CSRD reporting to tightening pharmacopeial standards, demands that companies demonstrate exactly where their ingredients come from, how they were produced, and what quality controls were applied at every step.